Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial

Rodney P. E. Pollard, Wayel H. Abdulahad, Arjan Vissink*, Nishath Hamza, Johannes G. M. Burgerhof, Jiska M. Meijer, Annie Visser, Minke G. Huitema, Fred K. L. Spijkervet, Cees G. M. Kallenberg, Hendrika Bootsma, Frans G. M. Kroese

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

51 Citations (Scopus)
234 Downloads (Pure)
Original languageEnglish
Pages (from-to)146-148
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume72
Issue number1
DOIs
Publication statusPublished - Jan-2013

Keywords

  • CELL-ACTIVATING FACTOR
  • TREATED PATIENTS

Cite this